BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008;26:5728-34. [PMID: 18981462 DOI: 10.1200/JCO.2008.17.6545] [Cited by in Crossref: 123] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (Ⅲ) -acute graft-versus-host disease (2020)]. Zhonghua Xue Ye Xue Za Zhi 2020;41:529-36. [PMID: 32549120 DOI: 10.3760/cma.j.issn.0253-2727.2020.07.001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
2 McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, Huff CA, Borrello I, Matsui WH, Brodsky RA, Ambinder RF, Bettinotti MP, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant 2018;24:343-52. [PMID: 29055682 DOI: 10.1016/j.bbmt.2017.10.023] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
3 Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem Cells Cloning 2010;3:105-17. [PMID: 24198516 DOI: 10.2147/SCCAA.S6815] [Cited by in Crossref: 18] [Cited by in F6Publishing: 35] [Article Influence: 1.5] [Reference Citation Analysis]
4 Le Bastard Q, Chevallier P, Montassier E. Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease. World J Gastroenterol 2021; 27(45): 7792-7800 [PMID: 34963742 DOI: 10.3748/wjg.v27.i45.7792] [Reference Citation Analysis]
5 Gebremedhin E, Behrendt CE, Nakamura R, Parker P, Salehian B. Severe hyperglycemia immediately after allogeneic hematopoietic stem-cell transplantation is predictive of acute graft-versus-host disease. Inflammation 2013;36:177-85. [PMID: 22987342 DOI: 10.1007/s10753-012-9533-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
6 Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, Mitchell SA, Datiles M, Hakim FT, Pavletic SZ, Cowen EW. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011;118:4250-7. [PMID: 21791415 DOI: 10.1182/blood-2011-04-350249] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
7 Isobe M, Konuma T, Masuko M, Uchida N, Miyakoshi S, Sugio Y, Yoshida S, Tanaka M, Matsuhashi Y, Hattori N, Onizuka M, Aotsuka N, Kouzai Y, Wake A, Kimura T, Ichinohe T, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. Ann Hematol 2021;100:1849-61. [PMID: 33624134 DOI: 10.1007/s00277-021-04464-5] [Reference Citation Analysis]
8 Omer AK, Weisdorf DJ, Lazaryan A, Shanley R, Blazar BR, MacMillan ML, Brunstein C, Bejanyan N, Arora M. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:879-83. [PMID: 26743342 DOI: 10.1016/j.bbmt.2015.12.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
9 Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115:3224-30. [PMID: 20124511 DOI: 10.1182/blood-2009-11-251595] [Cited by in Crossref: 252] [Cited by in F6Publishing: 234] [Article Influence: 21.0] [Reference Citation Analysis]
10 Lipof JJ, Loh KP, O'Dwyer K, Liesveld JL. Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. Cancers (Basel) 2018;10:E179. [PMID: 29866998 DOI: 10.3390/cancers10060179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Fu JB, Lee J, Smith DW, Guo Y, Bruera E. Return to primary service among bone marrow transplant rehabilitation inpatients: an index for predicting outcomes. Arch Phys Med Rehabil 2013;94:356-61. [PMID: 23022262 DOI: 10.1016/j.apmr.2012.08.219] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
12 Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 2010;30:75-101. [PMID: 20113888 DOI: 10.1016/j.iac.2009.10.001] [Cited by in Crossref: 112] [Cited by in F6Publishing: 95] [Article Influence: 9.3] [Reference Citation Analysis]
13 Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielcarek M, Fero ML, Warren EH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214-3219. [PMID: 21263156 DOI: 10.1182/blood-2010-08-302109] [Cited by in Crossref: 351] [Cited by in F6Publishing: 332] [Article Influence: 31.9] [Reference Citation Analysis]
14 Weschke DP, Leisenring WM, Lawler RL, Stevens-Ayers T, Huang ML, Jerome KR, Zerr DM, Hansen JA, Boeckh M, Hill JA. Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6. Biol Blood Marrow Transplant 2020;26:254-61. [PMID: 31678540 DOI: 10.1016/j.bbmt.2019.10.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 2013;121:2567-73. [PMID: 23361908 DOI: 10.1182/blood-2012-08-453860] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
16 Maung K, Ramalingam S, Chaudhry M, Ren Y, Jung SH, Romero K, Corbet K, Chao NJ, Choi T, Diehl AM, Diehl L, Gasparetto C, Horwitz M, Long GD, Lopez RD, Rizzieri DA, Sarantopoulos S, Sullivan KM, Bashir MR, Sung AD. Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS One 2020;15:e0238824. [PMID: 32915853 DOI: 10.1371/journal.pone.0238824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Fuji S, Kim SW, Yano S, Hagiwara S, Nakamae H, Hidaka M, Ito T, Ohashi K, Hatanaka K, Takami A, Kurosawa S, Yamashita T, Yamaguchi T, Fukuda T. A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F. Bone Marrow Transplant 2016;51:451-3. [PMID: 26551777 DOI: 10.1038/bmt.2015.268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
18 Chen GL, Zhang Y, Hahn T, Abrams S, Ross M, Liu H, McCarthy PL. Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning. Bone Marrow Transplant 2014;49:248-53. [PMID: 24162612 DOI: 10.1038/bmt.2013.167] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sun YQ, Han TT, Wang Y, Yan CH, Wang FR, Wang ZD, Kong J, Chen YH, Chen H, Han W, Chen Y, Zhang YY, Zhang XH, Xu LP, Liu KY, Huang XJ. Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. Front Oncol 2021;11:639502. [PMID: 33718234 DOI: 10.3389/fonc.2021.639502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ilett EE, Jørgensen M, Noguera-Julian M, Nørgaard JC, Daugaard G, Helleberg M, Paredes R, Murray DD, Lundgren J, MacPherson C, Reekie J, Sengeløv H. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients. Blood Adv 2020;4:5797-809. [PMID: 33232475 DOI: 10.1182/bloodadvances.2020002677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
21 Scroggins SM, Olivier AK, Meyerholz DK, Schlueter AJ. Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation. PLoS One 2013;8:e75158. [PMID: 24040397 DOI: 10.1371/journal.pone.0075158] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
22 Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, Bredeson CN, Carabasi MH, Gupta V, Hale GA. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29:805-813. [PMID: 21220593 DOI: 10.1200/jco.2010.32.5001] [Cited by in Crossref: 136] [Cited by in F6Publishing: 65] [Article Influence: 12.4] [Reference Citation Analysis]
23 Nakamura ZM, Nash RP, Quillen LJ, Richardson DR, McCall RC, Park EM. Psychiatric Care in Hematopoietic Stem Cell Transplantation. Psychosomatics. 2019;60:227-237. [PMID: 30733043 DOI: 10.1016/j.psym.2019.01.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
24 Arai Y, Kanda J, Nakasone H, Kondo T, Uchida N, Fukuda T, Ohashi K, Kaida K, Iwato K, Eto T, Kanda Y, Nakamae H, Nagamura-Inoue T, Morishima Y, Hirokawa M, Atsuta Y, Murata M; GVHD working group of the Japan Society for Hematopoietic Cell Transplantation. Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2016;51:96-102. [PMID: 26367230 DOI: 10.1038/bmt.2015.205] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
25 Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K, Kreyenberg H, Schubert R, Quadflieg M, Schneider D, Kühn MWM, Penack O, Zhang C, Möker N, Ullrich E. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J 2022;12:61. [PMID: 35418180 DOI: 10.1038/s41408-022-00660-2] [Reference Citation Analysis]
26 Sung AD, Chao NJ. Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol 2013;26:285-92. [PMID: 24309532 DOI: 10.1016/j.beha.2013.10.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
27 Mizuno S, Yanada M, Kawamura K, Masuko M, Uchida N, Ozawa Y, Iwato K, Ohashi K, Ikegame K, Kim SW, Tanaka M, Eto T, Kanda Y, Fukuda T, Atsuta Y, Yano S, Takami A. Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. Bone Marrow Transplant 2021;56:232-42. [PMID: 32737447 DOI: 10.1038/s41409-020-01011-0] [Reference Citation Analysis]
28 Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307. [PMID: 22010102 DOI: 10.1182/blood-2011-06-364265] [Cited by in Crossref: 356] [Cited by in F6Publishing: 338] [Article Influence: 32.4] [Reference Citation Analysis]
29 Dobbelstein C, Ahn KW, Haagenson M, Hale GA, van Rood JJ, Miklos D, Waller EK, Spellman SR, Fernandez-Vina M, Ganser A, Aljurf M, Bornhaeuser M, Gupta V, Marino SR, Pollack MS, Reddy V, Eder M, Lee SJ. Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2013;19:741-5. [PMID: 23380341 DOI: 10.1016/j.bbmt.2013.01.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, Hou J, Schwarzenberger P, Li QC, Zhang ZM. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014;7:59. [PMID: 25139202 DOI: 10.1186/s13045-014-0059-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
31 Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, Maris MB, Davis C, Deeg HJ, Lee SJ, Maloney DG, Sandmaier BM, Appelbaum FR, Gooley TA. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 2014;124:287-95. [PMID: 24797298 DOI: 10.1182/blood-2014-01-550566] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
32 Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, Ozawa Y, Kawano I, Atsuta Y, Kato K, Ichinohe T, Inoue M, Teshima T; JSHCT GVHD Working Group. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica 2016;101:1592-602. [PMID: 27662017 DOI: 10.3324/haematol.2016.149427] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
33 Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 2012;119:5030-6. [PMID: 22371885 DOI: 10.1182/blood-2011-11-389304] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 8.7] [Reference Citation Analysis]
34 Müller AM, Shashidhar S, Küpper NJ, Kohrt HE, Florek M, Negrin RS, Brown JM, Shizuru JA. Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proc Natl Acad Sci U S A 2012;109:5820-5. [PMID: 22440752 DOI: 10.1073/pnas.1120237109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
35 Nakasone H, Remberger M, Tian L, Brodin P, Sahaf B, Wu F, Mattsson J, Lowsky R, Negrin R, Miklos DB, Meyer E. Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica 2015;100:1477-85. [PMID: 26250581 DOI: 10.3324/haematol.2015.125294] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
36 Hosoba S, Waller EK, Shenvi N, Graiser M, Easley KA, Al-Kadhimi Z, Andoh A, Antun AG, Barclay S, Josephson CD, Koff JL, Khoury HJ, Langston AA, Zimring JC, Roback JD, Giver CR. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018;24:973-82. [PMID: 29307717 DOI: 10.1016/j.bbmt.2018.01.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
37 Harris AC, Ferrara JL, Levine JE. Advances in predicting acute GVHD. Br J Haematol 2013;160:288-302. [PMID: 23205489 DOI: 10.1111/bjh.12142] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.0] [Reference Citation Analysis]
38 Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross JR, Peets TK, Lumish MA, Shono Y, Dudakov JA, Poeck H, Hanash AM, Barker JN, Perales MA, Giralt SA, Pamer EG, van den Brink MR. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biol Blood Marrow Transplant 2015;21:1373-83. [PMID: 25977230 DOI: 10.1016/j.bbmt.2015.04.016] [Cited by in Crossref: 355] [Cited by in F6Publishing: 341] [Article Influence: 50.7] [Reference Citation Analysis]
39 Gupta A, Punatar S, Gawande J, Mathew L, Bagal B, Kannan S, Khattry N. Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant. Indian J Hematol Blood Transfus 2015;31:404-12. [PMID: 26306063 DOI: 10.1007/s12288-014-0499-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009;21:224-32. [PMID: 19304470 DOI: 10.1016/j.coi.2009.02.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
41 Paczesny S, Choi SW, Ferrara JL. Acute graft-versus-host disease: new treatment strategies. Curr Opin Hematol 2009;16:427-36. [PMID: 19812490 DOI: 10.1097/MOH.0b013e3283319a6f] [Cited by in Crossref: 51] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
42 Novota P, Zinöcker S, Norden J, Wang XN, Sviland L, Opitz L, Salinas-Riester G, Rolstad B, Dickinson AM, Walter L, Dressel R. Expression profiling of major histocompatibility and natural killer complex genes reveals candidates for controlling risk of graft versus host disease. PLoS One 2011;6:e16582. [PMID: 21305040 DOI: 10.1371/journal.pone.0016582] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
43 Hatanaka K, Fuji S, Ikegame K, Kato R, Wake A, Hidaka M, Ito T, Inoue M, Nagatoshi Y, Takami A, Uike N, Sakamaki H, Yabe H, Morishima Y, Suzuki R, Atsuta Y, Fukuda T. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin. Int J Hematol 2012;96:773-80. [PMID: 23132596 DOI: 10.1007/s12185-012-1209-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
44 Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant 2018;24:521-8. [PMID: 29155316 DOI: 10.1016/j.bbmt.2017.11.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
45 Fuji S, Takano K, Mori T, Eto T, Taniguchi S, Ohashi K, Sakamaki H, Morishima Y, Kato K, Miyamura K, Suzuki R, Fukuda T. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Bone Marrow Transplant 2014;49:1505-12. [PMID: 25111511 DOI: 10.1038/bmt.2014.178] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
46 Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 2020;4:5580-8. [PMID: 33170934 DOI: 10.1182/bloodadvances.2020002544] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
47 Kuriyama K, Fuji S, Inamoto Y, Tajima K, Tanaka T, Inoue Y, Ito R, Hayashi Y, Ito A, Kurosawa S, Kim SW, Yamashita T, Fukuda T. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol 2016;103:453-60. [PMID: 26857285 DOI: 10.1007/s12185-016-1947-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
48 Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You MJ, Gagea M, Ma Q, Molldrem JJ. Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. Leukemia 2016;30:1475-84. [PMID: 27055866 DOI: 10.1038/leu.2016.57] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
49 Leigh ND, Kokolus KM, O'Neill RE, Du W, Eng JW, Qiu J, Chen GL, McCarthy PL, Farrar JD, Cao X, Repasky EA. Housing Temperature-Induced Stress Is Suppressing Murine Graft-versus-Host Disease through β2-Adrenergic Receptor Signaling. J Immunol 2015;195:5045-54. [PMID: 26459348 DOI: 10.4049/jimmunol.1500700] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
50 Müller AM, Linderman JA, Florek M, Miklos D, Shizuru JA. Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proc Natl Acad Sci U S A 2010;107:14721-6. [PMID: 20679222 DOI: 10.1073/pnas.1009220107] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
51 Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010;17:493-9. [PMID: 20827187 DOI: 10.1097/MOH.0b013e32833eaf1b] [Cited by in Crossref: 69] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
52 Fuji S, Shindo T. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investig 2016;3:70. [PMID: 27868052 DOI: 10.21037/sci.2016.09.13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
53 Lim AB, Storek J, Beligaswatte A, Collins M, Tacey M, Williamson T, Mason K, Li E, Chaudhry MA, Russell JA, Daly A, Szer J, Lewis I, Ritchie D. Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis. Bone Marrow Transplant 2015;50:566-72. [PMID: 25642763 DOI: 10.1038/bmt.2014.313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med. 2013;2:25-32. [PMID: 23283494 DOI: 10.5966/sctm.2012-0115] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 8.1] [Reference Citation Analysis]
55 Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryan A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant 2019;25:1875-83. [PMID: 31085303 DOI: 10.1016/j.bbmt.2019.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol 2013;4:320-34. [PMID: 24082993 DOI: 10.1177/2040620713490316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
57 Pierini A, Ruggeri L, Carotti A, Falzetti F, Saldi S, Terenzi A, Zucchetti C, Ingrosso G, Zei T, Iacucci Ostini R, Piccinelli S, Bonato S, Tricarico S, Mancusi A, Ciardelli S, Limongello R, Merluzzi M, Di Ianni M, Tognellini R, Minelli O, Mecucci C, Martelli MP, Falini B, Martelli MF, Aristei C, Velardi A. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv 2021;5:1199-208. [PMID: 33646302 DOI: 10.1182/bloodadvances.2020003739] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
58 Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, Powell DJ Jr. High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 2016;30:1355-64. [PMID: 26898190 DOI: 10.1038/leu.2016.35] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
59 de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock C. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant 2018;24:2017-24. [PMID: 29933073 DOI: 10.1016/j.bbmt.2018.06.016] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 16.0] [Reference Citation Analysis]
60 Leventhal J, Huang Y, Xu H, Goode I, Ildstad ST. Novel regulatory therapies for prevention of Graft-versus-host disease. BMC Med 2012;10:48. [PMID: 22587383 DOI: 10.1186/1741-7015-10-48] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
61 Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R, Gerbitz A, Winkler J, Yeh SP, Hiemenz J, Christoph S, Lee DG, Wang PN, Holler E, Mielke S, Akard L, Yeo A, Ramachandra S, Smith K, Pertel P, Segal F. Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. Antimicrob Agents Chemother 2020;64:e02467-19. [PMID: 32015031 DOI: 10.1128/AAC.02467-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
62 Sanz J, Sanz GF. Umbilical cord blood transplantation from unrelated donors in adult patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 2010;23:217-22. [PMID: 20837333 DOI: 10.1016/j.beha.2010.05.001] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
63 Sever T, Kirkiz S, Kaya Z, Kocak U. Impact of peri-transplant RBC transfusion and ABO incompatibility on acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103352] [Reference Citation Analysis]